Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients

Inclusion Criteria:

* Subjects diagnosed with recurrent malignant lymphoma, which express B7 and FasR and have either failed to respond to standard therapy, relapsed and for whom no standard therapy is available.
* Measurable disease as measured by "Lugano" Classification.
* A measurable node must have a longest diameter (LDi) greater than 1.5 cm. Measurable extranodal disease (eg, hepatic nodules) may be included in the six representative, measured lesions. A measurable extranodal lesion should have an LDi greater than 1.0 cm
* Biopsy of tumor stains positive to cluster of differentiation 95 (CD95) and to Cluster of Differentiation 80 (CD80) or Cluster of Differentiation 86 (CD86) or both within the last 6 months.
* If greater than 6 months , a fine-needle aspiration (FNA) should be performed
* Men and Women age \> 18.
* Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 3.
* Estimated life expectancy of at least 2 months.
* Adequate liver function (serum bilirubin ≤2.0 mg/100 ml; alanine aminotransferase, aspartate aminotransferase ≤2× ULN).
* Adequate renal function (serum creatinine ≤1.5 mg/100 ml or creatinine clearance ≥30 ml/min/1.73m2 as measured by Cockcroft -Gault / CKD (Chronic Kidney Disease)/EPI (Epidemiology Collaboration) formulas.
* Platelet count ≥ 50,000 and an absolute neutrophil count (ANC) ≥ 1500 /mm3.
* Women of child bearing potential practicing an acceptable method of birth control.
* Understanding of study procedures and willingness to comply for the entire length of the study and to give written informed consent.

Exclusion Criteria:

* Other standard anti-neoplastic therapies are available.
* Known Central Nervous System (CNS) lymphoma.
* Chronic lymphocytic leukemia and autoimmunity leukemia.
* Known hypersensitivity to the study drug or to any of its components.
* Chronic heat failure (CHF) New-York heart association (NYHA) = Class IV.
* Known Chronic Obstructive Pulmonary Disease (COPD) \> Stage 3 (Forced Expiratory Volume -(FEV1)\<50%, FEV1/Forced Vital Capacity (FVC)\<70%).
* Chronic kidney disease (CKD) \>Stage 4 (subjects with known Filtration rate (FR)\<30 milliliter (mL)/min/1.73m2).
* Cirrhosis (Child-Pugh Class C score).
* Known hypersensitivity to drug components.
* Prior chemotherapy within 3 weeks, nitrosureas within 6 weeks, therapeutic anticancer antibodies within 3 weeks, radio or toxin immunoconjugates within 10 weeks, radiation therapy within 3 weeks, or major surgery within 28 days of first dose of the study drug.
* American Society for Cytotechnology (ASCT) and prior allogeneic stem cell transplantation (SCT)\< 12 weeks prior to first dose of the study drug.
* Myelosuppressive treatment within 2-3 weeks of entering this study. Prednisone allowed.
* Any other severe concurrent disease which in the judgment of the investigator would make the subject inappropriate for entry into this study.
* Positive test for acquired immune deficiency syndrome (AIDS).
* Any positive test for hepatitis B or hepatitis C virus (HBV or HCV) indicating acute or chronic infection (HBsAg, HBcAb total and anti-HCV Abs).
* Presence of uncontrolled infection.
* Evidence of active bleeding or bleeding susceptibility or medically significant hemorrhage within prior 30 days.
* Coumadin therapy.
* Pregnant or lactating.
* Treatment with other investigational drugs within 14 days of start of this study.
* Prisoners or subjects who are involuntarily incarcerated.
* Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.